Earnings

Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Aug 5, 2026 · 07:18 AM ET· updated 2h ago

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from

Why It Matters

Lifecore lost less money than expected this quarter, and made more sales than people predicted. This shows the company is improving and moving in a better direction, even though it's not yet profitable.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LFCR4.55

+0.20 (+4.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.